Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \>=30 kg/m2 and \<50 kg/m2 or a BMI \>=27 kg/m2 and \<50 kg/m2 in the presence of controlled hypertension and/or treated or untreated dyslipidemia~* Must have a stable weight, i.e., increasing or decreasing not more than 5% in the 3 months before screening~* Serum creatinine \<=1.5 mg/dL for men and \<=1.4 mg/dL for women at screening~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 2 times the upper limit of normal (ULN) and bilirubin within the normal range, unless the findings are consistent with Gilbert's disease~* fasting plasma glucose PG \<7.0 mmol/L (126 mg/dL) at screening~Exclusion Criteria:~* A history of hereditary glucose-galactose malabsorption or primary renal glycosuria~* An established diagnosis of diabetes mellitus or treatment with glucose lowering drugs at screening~* A history of reactive hypoglycemia or of symptomatology possibly due to hypoglycemia~* Fasting triglyceride level \>6.78 mmol/L (600 mg/dL) at screening~* History of obesity with a known cause (e.g., Cushing's disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 50 mg (Type: EXPERIMENTAL): Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).